{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:10:37Z","timestamp":1792383037187,"version":"4.4.0"},"reference-count":99,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,5]]},"abstract":"<jats:p>In this How I Treat article on Waldenstr\u00f6m macroglobulinemia, the authors present different case-based clinical scenarios and discuss available treatment options.<\/jats:p>","DOI":"10.1182\/blood.2019000725","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T22:19:06Z","timestamp":1568672346000},"page":"2022-2035","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":91,"title":["How I treat Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019120506584531300_B1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2019120506584531300_B2","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy","volume":"100","author":"Kastritis","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2019120506584531300_B3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/sonc.2003.50063","article-title":"Familial Waldenstrom\u2019s macroglobulinemia","volume":"30","author":"McMaster","year":"2003","journal-title":"Semin Oncol"},{"issue":"3","key":"2019120506584531300_B4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom\u2019s macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"2019120506584531300_B5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"2019120506584531300_B6","author":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017","edition":"Revised 4th ed"},{"issue":"16","key":"2019120506584531300_B7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression risk stratification of asymptomatic Waldenstr\u00f6m macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019120506584531300_B8","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019120506584531300_B9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/leu.2013.124","article-title":"Multiparameter flow cytometry for the identification of the Waldenstr\u00f6m\u2019s clone in IgM-MGUS and Waldenstr\u00f6m\u2019s Macroglobulinemia: new criteria for differential diagnosis and risk stratification","volume":"28","author":"Paiva","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019120506584531300_B10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"2019120506584531300_B11","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019120506584531300_B12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24955","article-title":"MYD88 mutation status does not impact overall survival in Waldenstr\u00f6m macroglobulinemia","volume":"93","author":"Abeykoon","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"2019120506584531300_B13","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/s41375-018-0197-7","article-title":"Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies","volume":"32","author":"Bagratuni","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2019120506584531300_B14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 Mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2019120506584531300_B15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2019120506584531300_B16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"2019120506584531300_B17","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib [published online ahead of print 3 July 2019]","author":"Castillo","journal-title":"Br J Haematol"},{"issue":"22","key":"2019120506584531300_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2952.2952","article-title":"Patients with Waldenstrom\u2019s macroglobulinemia are often hypoferremic that is refractory to oral iron repletion and responsive to parental iron infusions, and demonstrate elevated levels of hepcidin [abstract]","volume":"114","author":"Ciccarelli","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019120506584531300_B19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3324\/haematol.2009.010348","article-title":"IgA and IgG hypogammaglobulinemia in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"95","author":"Hunter","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2019120506584531300_B20","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1373\/clinchem.2009.124461","article-title":"Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry","volume":"55","author":"Murray","year":"2009","journal-title":"Clin Chem"},{"issue":"4","key":"2019120506584531300_B21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.14279","article-title":"Renal disease related to Waldenstr\u00f6m macroglobulinaemia: incidence, pathology and clinical outcomes","volume":"175","author":"Vos","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2019120506584531300_B22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2215\/CJN.13041117","article-title":"Kidney involvement of patients with Waldenstr\u00f6m macroglobulinemia and other IgM-producing B cell lymphoproliferative disorders","volume":"13","author":"Higgins","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2019120506584531300_B23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3816\/CLM.2009.n.027","article-title":"Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Menke","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"5","key":"2019120506584531300_B24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstr\u00f6m-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel","volume":"176","author":"D\u2019Sa","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"2019120506584531300_B25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp.2005.071175","article-title":"Peripheral neuropathies in Waldenstr\u00f6m\u2019s macroglobulinaemia","volume":"77","author":"Levine","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"2019120506584531300_B26","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","article-title":"European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis","volume":"34","author":"Sachchithanantham","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019120506584531300_B27","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.3324\/haematol.2018.190405","article-title":"True, true unrelated? Coexistence of Waldenstr\u00f6m macroglobulinemia and cardiac transthyretin amyloidosis","volume":"103","author":"Singh","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"2019120506584531300_B28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ajh.22044","article-title":"The role of 18F-FDG PET\/CT imaging in Waldenstrom macroglobulinemia","volume":"86","author":"Banwait","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"2019120506584531300_B29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjh.15201","article-title":"Prevalence and survival of smouldering Waldenstr\u00f6m macroglobulinaemia in the United States","volume":"184","author":"Pophali","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2019120506584531300_B30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2008-07-172080","article-title":"Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003","volume":"113","author":"Dhodapkar","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019120506584531300_B31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"issue":"10","key":"2019120506584531300_B32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019120506584531300_B33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.14743","article-title":"Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"177","author":"Gustine","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"2019120506584531300_B34","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/ajh.25254","article-title":"Predictors of symptomatic hyperviscosity in Waldenstr\u00f6m macroglobulinemia","volume":"93","author":"Abeykoon","year":"2018","journal-title":"Am J Hematol"},{"issue":"18","key":"2019120506584531300_B35","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"2019120506584531300_B36","article-title":"A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia [published online ahead of print 22 May 2019]","author":"Kastritis","journal-title":"Leukemia"},{"issue":"4","key":"2019120506584531300_B37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"issue":"20","key":"2019120506584531300_B38","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 mutation and its prognostic significance in Waldenstrom\u2019s macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019120506584531300_B39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CLM.2009.n.026","article-title":"Waldenstr\u00f6m\u2019s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia","volume":"9","author":"Stone","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"7","key":"2019120506584531300_B40","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/S2352-3026(18)30087-5","article-title":"Treatment and outcome patterns in European patients with Waldenstr\u00f6m\u2019s macroglobulinaemia: a large, observational, retrospective chart review","volume":"5","author":"Buske","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2019120506584531300_B41","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019120506584531300_B42","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u201cflare\u201d after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"11","key":"2019120506584531300_B43","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"9873","key":"2019120506584531300_B44","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"2019120506584531300_B45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.15718","article-title":"Bendamustine plus rituximab in newly-diagnosed Waldenstr\u00f6m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)","volume":"186","author":"Laribi","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"2019120506584531300_B46","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","article-title":"Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstr\u00f6m macroglobulinemia","volume":"56","author":"Tedeschi","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019120506584531300_B47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLML.2011.n.030","article-title":"Bendamustine therapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"11","author":"Treon","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2019120506584531300_B48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2019120506584531300_B49","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"2019120506584531300_B50","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019120506584531300_B51","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019120506584531300_B52","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom\u2019s macroglobulinemia: results of WMCTG Trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2019120506584531300_B53","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2019120506584531300_B54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1833.1833","article-title":"Long-term outcome of a prospective study of bortezomib, dexamethasone and rituximab (BDR) in previously untreated, symptomatic patients with Waldenstrom\u2019s macroglobulinemia [abstract]","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019120506584531300_B55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2019120506584531300_B56","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstr\u00f6m macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2019120506584531300_B57","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019120506584531300_B58","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","article-title":"Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease","volume":"118","author":"Tedeschi","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"2019120506584531300_B59","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ajh.24405","article-title":"Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom\u2019s macroglobulinemia","volume":"91","author":"Souchet","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2019120506584531300_B60","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1080\/10428194.2016.1233541","article-title":"Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed\/refractory Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"58","author":"Gavriatopoulou","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019120506584531300_B61","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019120506584531300_B62","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2019120506584531300_B63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"25","key":"2019120506584531300_B64","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"27","key":"2019120506584531300_B65","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019120506584531300_B66","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2019120506584531300_B67","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: Etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"2019120506584531300_B68","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-16-1918","article-title":"Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia (WMCTG 09-214)","volume":"23","author":"Treon","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019120506584531300_B69","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/leu.2015.164","article-title":"Phase I\/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed\/refractory Waldenstrom macroglobulinemia","volume":"29","author":"Ghobrial","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019120506584531300_B70","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2008-04-150854","article-title":"Thalidomide and rituximab in Waldenstrom macroglobulinemia","volume":"112","author":"Treon","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019120506584531300_B71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and rituximab in Waldenstrom\u2019s macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019120506584531300_B72","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.24175","article-title":"Lenalidomide is safe and active in Waldenstr\u00f6m macroglobulinemia","volume":"90","author":"Fouquet","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"2019120506584531300_B73","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019120506584531300_B74","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2018-04-846493","article-title":"Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine","volume":"132","author":"Manwani","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2019120506584531300_B75","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-09-806463","article-title":"First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival","volume":"131","author":"Pika","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2019120506584531300_B76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"issue":"24","key":"2019120506584531300_B77","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"2019120506584531300_B78","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.3324\/haematol.2013.087213","article-title":"Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients","volume":"98","author":"Hospital","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"2019120506584531300_B79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.13483","article-title":"Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients","volume":"172","author":"Vos","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019120506584531300_B80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study","volume":"133","author":"Castillo","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2019120506584531300_B81","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"2019120506584531300_B82","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.24366","article-title":"Atrial fibrillation associated with ibrutinib in Waldenstr\u00f6m macroglobulinemia","volume":"91","author":"Gustine","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"2019120506584531300_B83","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2019120506584531300_B84","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"2019120506584531300_B85","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2019120506584531300_B86","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"2019120506584531300_B87","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2019120506584531300_B88","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"2019120506584531300_B89","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstr\u00f6m macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019120506584531300_B90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3816\/CLM.2009.n.019","article-title":"Bortezomib in relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Chen","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"2019120506584531300_B91","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/10428194.2017.1321749","article-title":"Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series","volume":"59","author":"Vesole","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019120506584531300_B92","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"Once-weekly ofatumumab in untreated or relapsed Waldenstr\u00f6m\u2019s macroglobulinaemia: an open-label, single-arm, phase 2 study","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol"},{"key":"2019120506584531300_B93","first-page":"S854","author":"Castillo","year":"2018"},{"issue":"13","key":"2019120506584531300_B94","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"33","key":"2019120506584531300_B95","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstr\u00f6m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2019120506584531300_B96","article-title":"Indications for hematopoietic stem cell transplantation in patients with Waldenstrom\u2019s macroglobulinemia: a consensus project of the EBMT Lymphoma Working Party (LWP)\/European Consortium for Waldenstrom\u2019s Macroglobulinemia (ECWM)\/International Waldenstrom\u2019s Macroglobulinemia Foundation (IWMF) [abstract]","volume":"130","author":"Kyriakou","year":"2017","journal-title":"Blood"},{"key":"2019120506584531300_B97","author":"Owen","year":"2018"},{"issue":"1","key":"2019120506584531300_B98","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","article-title":"Update on treatment recommendations from the Fourth International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019120506584531300_B99","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstr\u00f6m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/23\/2022\/1545293\/bloodbld2019000725c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/23\/2022\/1545293\/bloodbld2019000725c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T06:59:27Z","timestamp":1575529167000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/23\/2022\/374984\/How-I-treat-Waldenstr%C3%B6m-macroglobulinemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":99,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000725","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]}}}